Brukinsa combined with R-CHOP is effective for DEL, with high response rates and acceptable safety. DEL is defined by MYC and BCL2 protein expression without gene rearrangements. Progression-free and ...

Overexpression of MYC and BCL2 in DLBCL is linked to increased CCL2 and CCR2, promoting M2 macrophage polarization and aggressiveness. Elevated CCL2 and CCR2 expression correlates with poor ...

Pivotal studies testing new options in previously untreated double-expressor (MYC/BCL2) diffuse large B-cell lymphoma (DLBCL) yielded differing results, according to findings presented at the recent ...

Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with ...

The terms PBMCs (peripheral blood mononuclear cells) and buffy coat are often used interchangeably. However, the products differ in terms of cell subset composition. PBMCs refer to the isolated ...

Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of cancer that originates within the lymphatic system. It has the potential to spread easily to multiple organ systems and tissues.

The mechanism of plant defense mediated by the non-expressor of pathogenesis-related (NPR) genes in monocots (plants having a single embryonic leaf) is not well-documented. Now, scientists have ...

Plasma expressor machine is a mechanical device used to separate plasma, platelets, and red blood cells. Plasma expressor contains a digital meter to note the readings, which exerts even pressure on ...

Large B-cell lymphomas, with an estimated 150,000 new cases annually worldwide, represent almost 30% of all cases of non-Hodgkin’s lymphoma. Patients typically present with progressive lymphadenopathy ...